Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;72(6):898-904.
doi: 10.1111/j.1365-2125.2011.04009.x.

Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database

Francois Chavant  1 , Sylvie Favrelière, Claire Lafay-Chebassier, Caroline Plazanet, Marie-Christine Pérault-Pochat
Affiliations

Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database

Francois Chavant et al. Br J Clin Pharmacol. 2011 Dec.

Abstract

Aims: To investigate putative associations of reports of memory disorders and suspected drugs.

Methods: We used the case/noncase method in the French PharmacoVigilance Database (FPVD). Cases were reports of memory loss in the FPVD between January 2000 and December 2009. Noncases were all other reports during the same period. To assess the association between memory impairment and drug intake, we calculated an odds ratio with its 95% confidence interval.

Results: Among the 188,284 adverse drug reactions recorded, we identified 519 cases of memory loss. The sex ratio was 0.6 and the median age was 54 years (range 4-93). The maximal number of cases occurred between 40-49 and 50-59 years. Evolution was favourable in 63% of the cases. We found significant odds ratios for benzodiazepines (alprazolam, bromazepam, prazepam, clonazepam etc.), benzodiazepine-like hypnotics (zolpidem and zopiclone), antidepressants (fluoxetine, paroxetine and venlafaxine), analgesics (morphine, nefopam and tramadol), anticonvulsants (topiramate, pregabalin, levetiracetam etc.), antipsychotics (aripiprazole and lithium) and other drugs, such as trihexyphenidyl, ciclosporin and isotretinoin.

Conclusions: Our study confirmed an association between memory disorders and some drugs, such as benzodiazepines and anticonvulsants. However, other drugs, such as benzodiazepine-like hypnotics, newer anticonvulsants, serotonin reuptake inhibitor antidepressants, isotretinoin and ciclosporin were significantly associated with memory disorders, although this was not described or poorly described in the literature. Taking account of the limits of this study in the FPVD (under-reporting, notoriety bias etc.), the case/noncase method allows assessment and detection of associations between exposure to drugs and a specific adverse drug reaction, such as memory disorders, and could thus generate signals and orientate us to further prospective studies to confirm such associations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Repartition of the 519 cases of memory disorders according to age
See this image and copyright information in PMC

Comment in

References

    1. Sellal F. [Transient amnesia in the elderly] Psychol Neuropsychiatr Vieil. 2006;4:31–8. - PubMed
    1. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332:455–9. - PMC - PubMed
    1. Favreliere S, Lafay-Chebassier C, Alkhidir F, Merlet I, Perault Pochat MC. [Drug-induced dementia: a case/non-case study in the French Pharmacovigilance database] Therapie. 2007;62:507–11. - PubMed
    1. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 1997;44:513–8. - PMC - PubMed
    1. Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL. [French pharmacovigilance database system: examples of utilisation] Therapie. 1995;50:557–62. - PubMed